research A retrospective review of paediatric alopecia areata cases seen in a tertiary institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Single-cell sequencing combined with spatial transcriptomics reveals the characteristics of follicle-targeted inflammation patterns in primary cicatricial alopecia
Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
research Alopecia Universalis: Never Give Up?
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies
Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
research Genetic Insights into Acne, Androgenetic Alopecia, and Alopecia Areata: Implications for Mechanisms and Precision Dermatology
Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
research AN UPDATE ON ETIOPATHOGENESIS AND MANAGEMENT OF ALOPECIA
Personalized treatment plans combining natural and synthetic approaches are important for managing alopecia effectively.
research Free Papers Medical and Surgical: Hair and Nails
The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders
The immune processes causing VKH and vitiligo are similar in dogs and humans.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
Biologics and JAK inhibitors may improve treatment for scarring alopecias.
research At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research CURRENT UNDERSTANDING OF VITILIGO: A COMPREHENSIVE LITERATURE REVIEW
Vitiligo is a systemic disease with psychological effects, and new treatments focus on personalized care.
research 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.